2019 ACR/ARP Annual Meeting

November 8-13, 2019. Atlanta, GA.

View by Number View by Title View Sessions

View by Date

Wednesday, November 13, 2019

11:00AM-12:30PM: Abstract Number: 2915

Machine-learning Classification Identifies a Subset of Patients That Improve on Abatacept via Modulation of a CD28-Related Pathway

6W023: Systemic Sclerosis & Related Disorder – Clinical III: Predictors of Outcome (2912–2917)

11:00AM-12:30PM: Abstract Number: 2918

Metabolic Signatures of Pathogenic T Cells in Medium and Large Vessel Vasculitis

6W024: Vasculitis – Non-ANCA-Associated & Related Disorders III: Large Vessel Vasculitis Pathogenesis & Imaging (2918–2923)

11:00AM-12:30PM: Abstract Number: 2912

Predictive Factors for Treatment Related Mortality and Event-Free Survival After Autologous Hematopoietic Stem Cell Transplantation for Systemic Sclerosis: Results of a Long Term Follow-up Multi-centre Study

6W023: Systemic Sclerosis & Related Disorder – Clinical III: Predictors of Outcome (2912–2917)

11:00AM-12:30PM: Abstract Number: 2914

Predictors to Develop Definite Systemic Sclerosis (SSc): Results from an International Multicentre Study on Very Early DiagnOsis of Systemic Sclerosis (VEDOSS)

6W023: Systemic Sclerosis & Related Disorder – Clinical III: Predictors of Outcome (2912–2917)

11:00AM-12:30PM: Abstract Number: 2908

Remission in Patients with Rheumatoid Arthritis Receiving Triple Therapy Compared to Biological Therapy – A Swedish Nationwide Register Study

6W021: RA – Treatments V: Switching & Tapering RA Medications (2906–2911)

11:00AM-12:30PM: Abstract Number: 2905

Rilonacept in Recurrent Pericarditis: Efficacy and Safety Data from an Ongoing Phase 2 Pilot Clinical Trial

6W020: Miscellaneous Rheumatic & Inflammatory Disease III: Novel Therapies (2900–2905)

11:00AM-12:30PM: Abstract Number: 2904

Rituximab as Rescue Therapy in Treatment-Refractory CTD-ILD

6W020: Miscellaneous Rheumatic & Inflammatory Disease III: Novel Therapies (2900–2905)

11:00AM-12:30PM: Abstract Number: 2913

Serum Interferon Score Predicts Clinical Outcome at 12 Months in Diffuse Cutaneous Systemic Sclerosis as Measured by Global Ranked Composite Score (GRCS) and Composite Response Index in SSc (CRISS)

6W023: Systemic Sclerosis & Related Disorder – Clinical III: Predictors of Outcome (2912–2917)

11:00AM-12:30PM: Abstract Number: 2925

The Effects of Leisure Time Sitting and Sitting at Work on Worsening Radiographic Knee Osteoarthritis over Two Years: Data from the Osteoarthritis Initiative

6W026: Epidemiology & Public Health (2924–2929)

11:00AM-12:30PM: Abstract Number: 2896

The Role of Alterations in the Splicing Machinery in the Pathogenesis of Lupus: Does It Impact Lupus Nephritis?

6W022: SLE – Etiology & Pathogenesis II (2894–2899)

11:00AM-12:30PM: Abstract Number: 2902

The Use and Safety of Rituximab in Connective Tissue Disease Associated Interstitial Lung Disease

6W020: Miscellaneous Rheumatic & Inflammatory Disease III: Novel Therapies (2900–2905)

11:00AM-12:30PM: Abstract Number: 2899

Transcriptomic Meta-analysis of Lupus Affected Tissues Reveals Shared Immune, Metabolic, and Biochemical Dysregulation

6W022: SLE – Etiology & Pathogenesis II (2894–2899)

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].